Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNISⓇ for Managing Lupus Nephritis - Seite 2

A propensity analysis of the Aspreva Lupus Management Study (ALMS) and AURORA 1 study suggested that LUPKYNIS^Ⓡ plus standard of care may reduce patient exposure to toxicities associated with taking mycophenolate mofetil (MMF) and glucocorticoids alone and demonstrated earlier reductions in proteinuria. Safety and efficacy outcomes for propensity-matched patients with active LN from the ALMS and AURORA 1 study were assessed at three and six months. The data showed an improved safety profile over the first six months of treatment with LUPKYNIS^Ⓡ in combination with low-dose glucocorticoids and lower-dose MMF without compromising efficacy. Patients who received the LUPKYNIS^Ⓡ -based regimen experienced reductions in exposure to glucocorticoids and MMF and earlier reductions in proteinuria compared to patients treated with higher doses of glucocorticoids and MMF.

In a subset analysis of three years of data from the AURORA Clinical Program, 44.4% of Black patients treated with LUPKYNIS^Ⓡ experienced an improvement in complete renal response at 36 months (n=18) compared to 14.3% of Black patients who achieved complete renal response when treated with MMF and glucocorticoids alone (n= 7). These findings among Black patients, a population that often experiences worse outcomes and lower responses to LN treatment, are consistent with the treatment response seen across all racial and ethnic groups treated with LUPKYNIS^Ⓡ in the AURORA Clinical Program.

“These data contribute to our growing body of evidence that LUPKYNIS^Ⓡ enables positive long-term kidney outcomes for people living with LN, a debilitating, yet common complication that occurs in about half of people with lupus,” said Dr. Greg Keenan, Chief Medical Officer of Aurinia. “The results presented at ASN this week demonstrate important clinical and mechanistic findings associated with LUPKYNIS^Ⓡ treatment. We remain deeply committed to improving the lives of people living with autoimmune diseases, by advancing transformative treatment options that are not only safe, but clinically meaningful, for long-term use.”

Additional poster presentations provided a view into current, new, and upcoming research.

Following is the complete guide to Aurinia’s presentations at ASN 2023:

Title: Repeat kidney biopsies from the AURORA 2 study of voclosporin in active lupus nephritis
Authors: Samir V. Parikh, Clint Abner, Ernie Yap, Krista Piper, Rob Huizinga, Henry Leher
Date: Thursday, November 2, 2023
Time: 5:42 p.m. – 5:51 p.m. ET